BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mir O, Coriat R, Ropert S, Cabanes L, Blanchet B, Camps S, Billemont B, Knebelmann B, Goldwasser F. Treatment of bevacizumab-induced hypertension by amlodipine. Invest New Drugs 2012;30:702-7. [PMID: 20878444 DOI: 10.1007/s10637-010-9549-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Krakoff LR. Identifiable Hypertension: A New Spectrum. J Clin Hypertens 2013;15:705-9. [DOI: 10.1111/jch.12153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Caletti S, Paini A, Coschignano MA, De Ciuceis C, Nardin M, Zulli R, Muiesan ML, Salvetti M, Rizzoni D. Management of VEGF-Targeted Therapy-Induced Hypertension. Curr Hypertens Rep 2018;20:68. [PMID: 29959593 DOI: 10.1007/s11906-018-0871-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kidoguchi S, Sugano N, Tokudome G, Yokoo T, Yano Y, Hatake K, Nishiyama A. New Concept of Onco-Hypertension and Future Perspectives. Hypertension 2021;77:16-27. [PMID: 33222548 DOI: 10.1161/HYPERTENSIONAHA.120.16044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Rao VU, Reeves DJ, Chugh AR, O'Quinn R, Fradley MG, Raghavendra M, Dent S, Barac A, Lenihan D. Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;77:2693-716. [PMID: 34045027 DOI: 10.1016/j.jacc.2021.04.009] [Reference Citation Analysis]
5 Guilhem A, Fargeton AE, Simon AC, Duffau P, Harle JR, Lavigne C, Carette MF, Bletry O, Kaminsky P, Leguy V, Lerolle N, Roux D, Lambert M, Chinet T, Bonnet D, Dupuis-Girod S, Rivière S. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients. PLoS One 2017;12:e0188943. [PMID: 29190827 DOI: 10.1371/journal.pone.0188943] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
6 Ivanyi P, Beutel G, Drewes N, Pirr J, Kielstein JT, Morgan M, Ganser A, Grünwald V. Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib. Clinical Genitourinary Cancer 2017;15:280-290.e3. [DOI: 10.1016/j.clgc.2016.10.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
7 Rodriguez-Pascual J, Cubillo A. Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review. Curr Pharmacogenomics Person Med 2017;15:81-5. [PMID: 29657584 DOI: 10.2174/1875692115666170815161754] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Hahn VS, Zhang KW, Sun L, Narayan V, Lenihan DJ, Ky B. Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection. Circ Res 2021;128:1576-93. [PMID: 33983833 DOI: 10.1161/CIRCRESAHA.121.318223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
9 Monsuez JJ. Detection and prevention of cardiac complications of cancer chemotherapy. Arch Cardiovasc Dis 2012;105:593-604. [PMID: 23177488 DOI: 10.1016/j.acvd.2012.04.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
10 Gougis P, Wassermann J, Spano JP, Keynan N, Funck-Brentano C, Salem JE. Clinical pharmacology of anti-angiogenic drugs in oncology. Crit Rev Oncol Hematol 2017;119:75-93. [PMID: 28916378 DOI: 10.1016/j.critrevonc.2017.08.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
11 Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol 2014;30:534-43. [PMID: 24786444 DOI: 10.1016/j.cjca.2014.02.011] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 8.9] [Reference Citation Analysis]
12 Waliany S, Sainani KL, Park LS, Zhang CA, Srinivas S, Witteles RM. Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor. JACC CardioOncol 2019;1:24-36. [PMID: 34396159 DOI: 10.1016/j.jaccao.2019.08.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
13 van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, Mathijssen RHJ, Danser AHJ, Lang NN. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circ Res 2021;128:1040-61. [PMID: 33793337 DOI: 10.1161/CIRCRESAHA.121.318051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Santoni M, Conti A, Massari F, Di Nunno V, Faloppi L, Galizia E, Morbiducci J, Piva F, Buti S, Iacovelli R, Ferretti B, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Battelli N, Montironi R. Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Rev Cardiovasc Ther 2019;17:917-27. [PMID: 31829045 DOI: 10.1080/14779072.2019.1704626] [Reference Citation Analysis]
15 Brinda BJ, Viganego F, Vo T, Dolan D, Fradley MG. Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options. Curr Treat Options Cardio Med 2016;18. [DOI: 10.1007/s11936-016-0452-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
16 Patel S, Dushenkov A, Jungsuwadee P, Krishnaswami A, Barac A. Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors. J Cardiovasc Transl Res 2020;13:463-77. [PMID: 32430701 DOI: 10.1007/s12265-020-10024-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Lefebvre J, Glezerman IG. Kidney Toxicities Associated With Novel Cancer Therapies. Adv Chronic Kidney Dis 2017;24:233-40. [PMID: 28778363 DOI: 10.1053/j.ackd.2017.05.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
18 Jouinot A, Coriat R, Huillard O, Goldwasser F. Les biothérapies des cancers colorectaux métastatiques en 2014. La Presse Médicale 2014;43:1056-66. [DOI: 10.1016/j.lpm.2014.03.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens. 2011;2011:236239. [PMID: 21423678 DOI: 10.4061/2011/236239] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
20 Guha A, Armanious M, Fradley MG. Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine 2019;29:29-39. [DOI: 10.1016/j.tcm.2018.06.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
21 Plummer C, Michael A, Shaikh G, Stewart M, Buckley L, Miles T, Ograbek A, McCormack T. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. Br J Cancer 2019;121:109-16. [PMID: 31182765 DOI: 10.1038/s41416-019-0481-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
22 Damrongwatanasuk R, Fradley MG. Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia. Curr Treat Options Cardiovasc Med 2017;19:24. [PMID: 28316033 DOI: 10.1007/s11936-017-0524-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
23 Abdel-Rahman O, ElHalawani H. Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents. Crit Rev Oncol Hematol 2016;102:89-100. [PMID: 27129437 DOI: 10.1016/j.critrevonc.2016.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Sanidas E, Papadopoulos DP, Velliou M, Tsioufis K, Mantzourani M, Iliopoulos D, Perrea D, Barbetseas J, Papademetriou V. The Role of Angiogenesis Inhibitors in Hypertension: Following "Ariadne's Thread". Am J Hypertens 2018;31:961-9. [PMID: 29788148 DOI: 10.1093/ajh/hpy087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Li Y, Li S, Zhu Y, Liang X, Meng H, Chen J, Zhang D, Guo H, Shi B. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2014;16:177-85. [PMID: 24621095 DOI: 10.1111/jch.12273] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
26 Alivon M, Giroux J, Briet M, Goldwasser F, Laurent S, Boutouyrie P. Large artery stiffness and hypertension after antiangiogenic drugs: influence on cancer progression. J Hypertens 2015;33:1310-7. [PMID: 25715093 DOI: 10.1097/HJH.0000000000000550] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
27 Okwuosa TM, Anzevino S, Rao R. Cardiovascular disease in cancer survivors. Postgrad Med J 2017;93:82-90. [PMID: 28123076 DOI: 10.1136/postgradmedj-2016-134417] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
28 Shin S, Noh Y. Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials. Ther Clin Risk Manag 2018;14:833-47. [PMID: 29765225 DOI: 10.2147/TCRM.S148840] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Hassen LJ, Lenihan DJ, Baliga RR. Hypertension in the Cardio-Oncology Clinic. Heart Fail Clin 2019;15:487-95. [PMID: 31472884 DOI: 10.1016/j.hfc.2019.06.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
30 Agarwal M, Thareja N, Benjamin M, Akhondi A, Mitchell GD. Tyrosine Kinase Inhibitor-Induced Hypertension. Curr Oncol Rep 2018;20. [DOI: 10.1007/s11912-018-0708-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
31 de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD. Management of antiangiogenic therapy-induced hypertension. Hypertension 2012;60:607-15. [PMID: 22851729 DOI: 10.1161/HYPERTENSIONAHA.112.196774] [Cited by in Crossref: 76] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
32 Cameron AC, Welsh P, Neves KB, Newby DE, Touyz RM, Lang NN. Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation. J Hypertens 2020;38:257-65. [PMID: 31449168 DOI: 10.1097/HJH.0000000000002230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]